58 results
424B5
OCUP
Ocuphire Pharma Inc
14 Aug 23
Prospectus supplement for primary offering
8:00am
adversely affect Ocuphire’s revenues from the sales of a drug, if any.
In some countries, particularly in the European Union, the pricing
8-K
EX-10.1
OCUP
Ocuphire Pharma Inc
11 Aug 23
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
9:27am
Assets Control (“OFAC”), the United Nations Security Council (“UNSC”), the European Union (“EU”), His Majesty’s Treasury (“HMT”), or other relevant … and regulations, including without limitation HIPAA, CCPA, and the European Union General Data Protection Regulation (EU 2016/679) (collectively, the “Privacy
8-K
EX-10.1
9ccp8
23 Jun 21
Entry into a Material Definitive Agreement
4:15pm
424B5
ngrcsnxg
7 Jun 21
Prospectus supplement for primary offering
4:21pm
8-K/A
EX-10.1
n13x6
7 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:05pm
8-K
EX-10.1
h5r zheoad941bw19
4 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:48pm
424B5
kkrqza6w8i5u
11 Mar 21
Prospectus supplement for primary offering
9:19am
8-K
EX-1.1
d1ki3f
11 Mar 21
Entry into a Material Definitive Agreement
8:34am
424B4
fvhnum5p
17 Feb 21
Prospectus supplement with pricing info
7:14am
424B3
gw5dphp x78
2 Oct 20
Prospectus supplement
9:25am
S-4/A
mc4f4b
27 Aug 20
Registration of securities issued in business combination transactions (amended)
5:04pm
S-4/A
EX-10.45
tfxfxkv1b g3dxn
27 Aug 20
Registration of securities issued in business combination transactions (amended)
5:04pm